表紙:腫瘍学向けバイオシミラーの世界市場(2022年~2028年):適応症別、医薬品クラス別、投与経路別、エンドユーザー別、流通チャネル別、地域別の市場規模調査と予測
市場調査レポート
商品コード
1084116

腫瘍学向けバイオシミラーの世界市場(2022年~2028年):適応症別、医薬品クラス別、投与経路別、エンドユーザー別、流通チャネル別、地域別の市場規模調査と予測

Global Oncology Biosimilars Market Size study, By Indication, By Drug Class, By Route of Administration, By End-Users, By Distribution Channel, and Regional Forecasts 2022-2028

出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.18円
腫瘍学向けバイオシミラーの世界市場(2022年~2028年):適応症別、医薬品クラス別、投与経路別、エンドユーザー別、流通チャネル別、地域別の市場規模調査と予測
出版日: 2022年05月31日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の腫瘍学向けバイオシミラーの市場規模は、2022年~2028年の予測期間中に健全な成長率で拡大すると予想されています。市場を牽引する主な要因には、世界のがんの有病率の増加、手頃な価格によるバイオシミラー医薬品の需要の増加、大手企業による最近のパートナーシップと製品の発売などがあります。しかし、医薬品開発・販売に関連する高コストや医薬品開発・承認の複雑なプロセスが、予測期間における市場の成長を阻害しています。

当レポートでは、世界の腫瘍学向けバイオシミラー市場を調査し、市場の概要、市場の促進要因・抑制要因の分析、市場機会、COVID-19の影響、セグメント別の市場分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の腫瘍学向けバイオシミラー市場:定義と範囲

第3章 世界の腫瘍学向けバイオシミラー:市場力学

  • 腫瘍学向けバイオシミラー市場:影響分析(2020年~2028年)

第4章 世界の腫瘍学向けバイオシミラー市場:業界分析

  • ポーターのファイブフォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの推奨事項と結論
  • 主要な投資機会
  • 主要な成功戦略

第5章 リスク評価:COVID-19の影響

    • 業界に対するCOVID-19の全体的な影響の評価
    • COVID-19以前およびCOVID-19後の市場シナリオ

第6章 世界の腫瘍学向けバイオシミラー市場:適応症別

  • 市場のスナップショット
  • 実績:潜在的な分析
  • 市場規模の推計と予測(2018年~2028年)
  • サブセグメント分析
    • 乳がん
    • 肺がん
    • 結腸直腸がん
    • 子宮頸がん
    • 血液がん
    • その他

第7章 世界の腫瘍学向けバイオシミラー市場:医薬品クラス別

  • 市場のスナップショット
  • 実績:潜在的な分析
  • 市場規模の推計と予測(2018年~2028年)
  • サブセグメント分析
    • モノクローナル抗体
    • 顆粒球コロニー刺激因子
    • その他

第8章 世界の腫瘍学向けバイオシミラー市場:投与経路別

  • 市場のスナップショット
  • 実績:潜在的な分析
  • 市場規模の推計と予測(2018年~2028年)
  • サブセグメント分析
    • 静脈内
    • 皮下
    • その他

第9章 世界の腫瘍学向けバイオシミラー市場:エンドユーザー別

  • 市場のスナップショット
  • 実績:潜在的な分析
  • 市場規模の推計と予測(2018年~2028年)
  • サブセグメント分析
    • 病院
    • 専門診療所
    • 在宅医療
    • その他

第10章 世界の腫瘍学向けバイオシミラー市場:流通チャネル別

  • 市場のスナップショット
  • 実績:潜在的な分析
  • 市場規模の推計と予測(2018年~2028年)
  • サブセグメント分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局
    • その他

第11章 世界の腫瘍学向けバイオシミラー市場:地域分析

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州のスナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋地域のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカのスナップショット
    • ブラジル
    • メキシコ
  • その他の地域

第12章 競合情勢

  • 主な市場戦略
  • 企業プロファイル
    • Pfizer Inc.(米国)
    • GlaxoSmithKline plc(英国)
    • Novartis AG(スイス)
    • Mylan N.V.(米国)
    • Teva Pharmaceutical Industries Ltd.(イスラエル)
    • Sanofi(フランス)
    • F. Hoffmann-La Roche Ltd.(スイス)
    • Zydus Cadila(インド)
    • Lupin(インド)
    • Amneal Pharmaceuticals LLC.(米国)

第13章 調査プロセス

図表

LIST OF TABLES

List of Tables

  • TABLE 1. Global Oncology Biosimilars Market, report scope
  • TABLE 2. Global Oncology Biosimilars Market estimates & forecasts by Region 2018-2028 (USD Million)
  • TABLE 3. Global Oncology Biosimilars Market estimates & forecasts by Indication 2018-2028 (USD Million)
  • TABLE 4. Global Oncology Biosimilars Market estimates & forecasts by Drug Class 2018-2028 (USD Million)
  • TABLE 5. Global Oncology Biosimilars Market estimates & forecasts by Route of Administration 2018-2028 (USD Million)
  • TABLE 6. Global Oncology Biosimilars Market estimates & forecasts by End-Users 2018-2028 (USD Million)
  • TABLE 7. Global Oncology Biosimilars Market estimates & forecasts by Distribution Channel 2018-2028 (USD Million)
  • TABLE 8. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 9. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 10. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 11. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 12. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 13. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 14. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 15. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 16. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 17. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 18. U.S. Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 19. U.S. Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 20. U.S. Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 21. Canada Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 22. Canada Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 23. Canada Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 24. UK Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 25. UK Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 26. UK Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 27. Germany Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 28. Germany Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 29. Germany Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 30. RoE Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 31. RoE Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 32. RoE Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 33. China Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 34. China Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 35. China Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 36. India Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 37. India Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 38. India Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 39. Japan Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 40. Japan Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 41. Japan Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 42. RoAPAC Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 43. RoAPAC Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 44. RoAPAC Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 45. Brazil Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 46. Brazil Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 47. Brazil Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 48. Mexico Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 49. Mexico Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 50. Mexico Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 51. RoLA Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 52. RoLA Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 53. RoLA Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 54. Row Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 55. Row Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 56. Row Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 57. List of secondary sources, used in the study of global Oncology Biosimilars Market
  • TABLE 58. List of primary sources, used in the study of global Oncology Biosimilars Market
  • TABLE 59. Years considered for the study
  • TABLE 60. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Oncology Biosimilars Market, research methodology
  • FIG 2. Global Oncology Biosimilars Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Oncology Biosimilars Market, key trends 2021
  • FIG 5. Global Oncology Biosimilars Market, growth prospects 2022-2028
  • FIG 6. Global Oncology Biosimilars Market, porters 5 force model
  • FIG 7. Global Oncology Biosimilars Market, pest analysis
  • FIG 8. Global Oncology Biosimilars Market, value chain analysis
  • FIG 9. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
  • FIG 10. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
  • FIG 11. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
  • FIG 12. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
  • FIG 13. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
  • FIG 14. Global Oncology Biosimilars Market, regional snapshot 2018 & 2028
  • FIG 15. North America Oncology Biosimilars Market 2018 & 2028 (USD Million)
  • FIG 16. Europe Oncology Biosimilars Market 2018 & 2028 (USD Million)
  • FIG 17. Asia pacific Market 2018 & 2028 (USD Million)
  • FIG 18. Latin America Oncology Biosimilars Market 2018 & 2028 (USD Million)
  • FIG 19. Global Oncology Biosimilars Market, company Market share analysis (2021)
目次

Global Oncology Biosimilars Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Oncology Biosimilars can be defined as a version of a known and proven biologic drug. These drugs are made from living things such as cells, tissues, or proteins. Biosimilars are more affordable alternatives to similar other drugs. Also, biosimilar offers similar safety and toxicity profile. Growing prevalence of cancer worldwide and increasing demand for biosimilar drugs due to affordability as well as recent partnerships and product launches from leading players are key drivers for growth of Oncology Biosimilars Market. For instance, according to World Cancer Research Fund - in 2020, around 18.1 million cancer cases were reported globally. Around 9.3 million cases were in men and 8.8 million in women. Further, Breast and lung cancers were most prevalent type of cancers worldwide, contributing 12.5% and 12.2% of all cancer cases reported in 2020. Moreover, in March 2019, the United States (U.S.) Food and Drug Administration (FDA) has approved new biosimilar from Pfizer Inc. named TRAZIMERA (trastuzumab-qyyp). This new drug is a biosimilar to Herceptin (trastuzumab). This new drug is intended for the treatment of breast cancer and Esophageal cancer. Further, in March 2022, Cipla Medpro, a wholly owned subsidiary of Cipla Limited, India entered in a partnership agreement with Madrid, Spain based mAbxience. Under this partnership both the companies would work towards bringing oncology and respiratory-related biosimilars to South Africa region. Also, growing spending on pharmaceuticals research and rising healthcare infrastructure in emerging economies are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high cost associated with the drug development & distribution and complex process of drug development and approvals impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Oncology Biosimilars Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to rising R&D activities and increasing prevalence of cancer as well as presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing number of pharmaceutical contract manufacturers and rising healthcare spending in the region, would create lucrative growth prospects for the Oncology Biosimilars Market across the Asia Pacific region.

Major market players included in this report are:

Pfizer Inc. (U.S.)

GlaxoSmithKline plc (U.K.)

Novartis AG (Switzerland)

Mylan N.V. (U.S.)

Teva Pharmaceutical Industries Ltd.(Israel)

Sanofi (France)

F. Hoffmann-La Roche Ltd. (Switzerland)

Zydus Cadila (India)

Lupin (India)

Amneal Pharmaceuticals LLC. (U.S.)

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Indication

Breast Cancer

Lung Cancer

Colorectal Cancer

Cervical Cancer

Blood Cancer

Others

By Drug Class

Monoclonal Antibodies

Granulocyte Colony-Stimulating Factor

Others

By Route of Administration

Intravenous

Subcutaneous

Others

By End-Users

Hospitals

Specialty Clinics

Homecare

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Oncology Biosimilars Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
    • 1.2.1. Global Oncology Biosimilars Market, by Region, 2020-2028 (USD Million)
    • 1.2.2. Global Oncology Biosimilars Market, by Indication, 2020-2028 (USD Million)
    • 1.2.3. Global Oncology Biosimilars Market, by Drug Class, 2020-2028 (USD Million)
    • 1.2.4. Global Oncology Biosimilars Market, by Route of Administration, 2020-2028 (USD Million)
    • 1.2.5. Global Oncology Biosimilars Market, by End-Users, 2020-2028 (USD Million)
    • 1.2.6. Global Oncology Biosimilars Market, by Distribution Channel, 2020-2028 (USD Million)
    • 1.2.7.
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Oncology Biosimilars Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Oncology Biosimilars Market Dynamics

  • 3.1. Oncology Biosimilars Market Impact Analysis (2020-2028)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Growing prevalence of cancer worldwide.
      • 3.1.1.2. increasing demand for biosimilar drugs due to affordability.
      • 3.1.1.3. Recent partnerships and product launches from leading players.
    • 3.1.2. Market Challenges
      • 3.1.2.1. high cost associated with the drug development & distribution.
      • 3.1.2.2. Complex process of drug development and approvals.
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing spending on pharmaceuticals research.
      • 3.1.3.2. Rising healthcare infrastructure in emerging economies.

Chapter 4. Global Oncology Biosimilars Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion
  • 4.5. Top investment opportunity
  • 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

    • 5.1.1. Assessment of the overall impact of COVID-19 on the industry
    • 5.1.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Oncology Biosimilars Market, by Indication

  • 6.1. Market Snapshot
  • 6.2. Global Oncology Biosimilars Market by Indication, Performance - Potential Analysis
  • 6.3. Global Oncology Biosimilars Market Estimates & Forecasts by Indication 2018-2028 (USD Million)
  • 6.4. Oncology Biosimilars Market, Sub Segment Analysis
    • 6.4.1. Breast Cancer
    • 6.4.2. Lung Cancer
    • 6.4.3. Colorectal Cancer
    • 6.4.4. Cervical Cancer
    • 6.4.5. Blood Cancer
    • 6.4.6. Others

Chapter 7. Global Oncology Biosimilars Market, by Drug Class

  • 7.1. Market Snapshot
  • 7.2. Global Oncology Biosimilars Market by Drug Class, Performance - Potential Analysis
  • 7.3. Global Oncology Biosimilars Market Estimates & Forecasts by Drug Class 2018-2028 (USD Million)
  • 7.4. Oncology Biosimilars Market, Sub Segment Analysis
    • 7.4.1. Monoclonal Antibodies
    • 7.4.2. Granulocyte Colony-Stimulating Factor
    • 7.4.3. Others

Chapter 8. Global Oncology Biosimilars Market, by Route of Administration

  • 8.1. Market Snapshot
  • 8.2. Global Oncology Biosimilars Market by Route of Administration, Performance - Potential Analysis
  • 8.3. Global Oncology Biosimilars Market Estimates & Forecasts by Route of Administration 2018-2028 (USD Million)
  • 8.4. Oncology Biosimilars Market, Sub Segment Analysis
    • 8.4.1. Intravenous
    • 8.4.2. Subcutaneous
    • 8.4.3. Others

Chapter 9. Global Oncology Biosimilars Market, by End-Users

  • 9.1. Market Snapshot
  • 9.2. Global Oncology Biosimilars Market by End-Users, Performance - Potential Analysis
  • 9.3. Global Oncology Biosimilars Market Estimates & Forecasts by End-Users 2018-2028 (USD Million)
  • 9.4. Oncology Biosimilars Market, Sub Segment Analysis
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
    • 9.4.3. Homecare
    • 9.4.4. Others

Chapter 10. Global Oncology Biosimilars Market, by Distribution Channel

  • 10.1. Market Snapshot
  • 10.2. Global Oncology Biosimilars Market by Distribution Channel, Performance - Potential Analysis
  • 10.3. Global Oncology Biosimilars Market Estimates & Forecasts by Distribution Channel 2018-2028 (USD Million)
  • 10.4. Oncology Biosimilars Market, Sub Segment Analysis
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
    • 10.4.4. Others

Chapter 11. Global Oncology Biosimilars Market, Regional Analysis

  • 11.1. Oncology Biosimilars Market, Regional Market Snapshot
  • 11.2. North America Oncology Biosimilars Market
    • 11.2.1. U.S. Oncology Biosimilars Market
      • 11.2.1.1. Indication estimates & forecasts, 2018-2028
      • 11.2.1.2. Drug Class estimates & forecasts, 2018-2028
      • 11.2.1.3. Route of Administration estimates & forecasts, 2018-2028
      • 11.2.1.4. End-Users estimates & forecasts, 2018-2028
      • 11.2.1.5. Distribution Channel estimates & forecasts, 2018-2028
    • 11.2.2. Canada Oncology Biosimilars Market
  • 11.3. Europe Oncology Biosimilars Market Snapshot
    • 11.3.1. U.K. Oncology Biosimilars Market
    • 11.3.2. Germany Oncology Biosimilars Market
    • 11.3.3. France Oncology Biosimilars Market
    • 11.3.4. Spain Oncology Biosimilars Market
    • 11.3.5. Italy Oncology Biosimilars Market
    • 11.3.6. Rest of Europe Oncology Biosimilars Market
  • 11.4. Asia-Pacific Oncology Biosimilars Market Snapshot
    • 11.4.1. China Oncology Biosimilars Market
    • 11.4.2. India Oncology Biosimilars Market
    • 11.4.3. Japan Oncology Biosimilars Market
    • 11.4.4. Australia Oncology Biosimilars Market
    • 11.4.5. South Korea Oncology Biosimilars Market
    • 11.4.6. Rest of Asia Pacific Oncology Biosimilars Market
  • 11.5. Latin America Oncology Biosimilars Market Snapshot
    • 11.5.1. Brazil Oncology Biosimilars Market
    • 11.5.2. Mexico Oncology Biosimilars Market
  • 11.6. Rest of The World Oncology Biosimilars Market

Chapter 12. Competitive Intelligence

  • 12.1. Top Market Strategies
  • 12.2. Company Profiles
    • 12.2.1. Pfizer Inc. (US)
      • 12.2.1.1. Key Information
      • 12.2.1.2. Overview
      • 12.2.1.3. Financial (Subject to Data Availability)
      • 12.2.1.4. Product Summary
      • 12.2.1.5. Recent Developments
    • 12.2.2. GlaxoSmithKline plc (U.K.)
    • 12.2.3. Novartis AG (Switzerland)
    • 12.2.4. Mylan N.V. (U.S.)
    • 12.2.5. Teva Pharmaceutical Industries Ltd. (Israel)
    • 12.2.6. Sanofi (France)
    • 12.2.7. F. Hoffmann-La Roche Ltd. (Switzerland)
    • 12.2.8. Zydus Cadila (India)
    • 12.2.9. Lupin (India)
    • 12.2.10. Amneal Pharmaceuticals LLC. (U.S.)

Chapter 13. Research Process

  • 13.1. Research Process
    • 13.1.1. Data Mining
    • 13.1.2. Analysis
    • 13.1.3. Market Estimation
    • 13.1.4. Validation
    • 13.1.5. Publishing
  • 13.2. Research Attributes
  • 13.3. Research Assumption